Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High - What's Next?

Key Points

• Shares of Pharvaris reached a new 52‑week high, trading as high as $29.80 (last $29.64) on heavy volume and were up roughly 4.4% during the session.
• Analysts maintain a consensus rating of Moderate Buy (10 Buys, 2 Holds, 1 Sell) with an average price target of $41.70, and several firms recently raised targets—e.g., HC Wainwright $60, Oppenheimer $50, Bank of America $30.
• Pharvaris is a clinical‑stage biopharma focused on hereditary angioedema, with lead program PHA121 an investigational once‑daily oral plasma kallikrein inhibitor; the company has a market cap of about $1.6 billion.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $29.80 and last traded at $29.64, with a volume of 341365 shares trading hands. The stock had previously closed at $28.25.

Analyst Ratings Changes

A number of analysts have recently weighed in on PHVS shares. Bank of America increased their target price on shares of Pharvaris from $27.00 to $30.00 and gave the stock a "neutral" rating in a report on Thursday, December 4th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Wall Street Zen upgraded Pharvaris from a "sell" rating to a "hold" rating in a report on Saturday. Oppenheimer lifted their price objective on Pharvaris from $44.00 to $50.00 and gave the stock an "outperform" rating in a research report on Thursday, December 4th. Finally, Leerink Partners set a $38.00 target price on Pharvaris in a research note on Wednesday, December 3rd. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Pharvaris presently has a consensus rating of "Moderate Buy" and an average price target of $41.70.

Pharvaris Stock Up 4.4%

The firm's 50-day moving average is $26.99 and its 200-day moving average is $25.33. The company has a market cap of $1.60 billion, a PE ratio of -9.20 and a beta of -2.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock worth $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc grew its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after purchasing an additional 1,695 shares during the period. Amundi grew its stake in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company's stock worth $489,000 after purchasing an additional 27,416 shares during the period. Finally, HighVista Strategies LLC raised its holdings in Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company's stock worth $418,000 after purchasing an additional 971 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.